# Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies

> **NCT02315118** · PHASE1,PHASE2 · UNKNOWN · sponsor: **National University Hospital, Singapore** · enrollment: 18 (estimated)

## Conditions studied

- B-Cell Chronic Lymphocytic Leukemia
- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** T-cell therapy + Rituximab + IL-2

## Key facts

- **NCT ID:** NCT02315118
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-12
- **Primary completion:** 2017-12
- **Final completion:** 2018-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2016-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02315118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02315118, "Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT02315118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*